Moleculin Biotech, Inc. (MBRX)

NASDAQ: MBRX · IEX Real-Time Price · USD
1.62
-0.01 (-0.61%)
At close: Aug 12, 2022 4:00 PM
1.64
+0.02 (1.23%)
After-hours: Aug 12, 2022 6:14 PM EDT
-0.61%
Market Cap 46.30M
Revenue (ttm) n/a
Net Income (ttm) -18.32M
Shares Out 28.58M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 48,512
Open 1.62
Previous Close 1.63
Day's Range 1.62 - 1.65
52-Week Range 1.02 - 3.20
Beta 1.78
Analysts Buy
Price Target 12.64 (+680.2%)
Earnings Date Aug 10, 2022

About MBRX

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other m... [Read more...]

Industry Biotechnology
IPO Date Jun 2, 2016
Employees 13
Stock Exchange NASDAQ
Ticker Symbol MBRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for MBRX stock is "Buy." The 12-month stock price forecast is 12.64, which is an increase of 680.25% from the latest price.

Price Target
$12.64
(680.25% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft T...

– Preliminary Phase 1b data demonstrated clinical activity, defined as stable disease or better – Company determines RP2D to be 360 mg/m2 and will begin Phase 2 recruitment – Annamycin has Fast Track St...

Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in t...

– Preliminary results of second cohort in the first-in-human Phase 1a allow Company to proceed to 32 mg/kg dose of WP1122 in third cohort toward establishing maximum tolerated dose (MTD) – – Multiple as...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Moleculin Biotech, Inc. for Potential Breaches of Fiducia...

NEW YORK , July 5, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim in...

Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in th...

– Preliminary results of first cohort in the first-in-human Phase 1a allows Company to proceed to 16 mg/kg dose of WP1122 in second cohort toward establishing maximum tolerated dose (MTD) –   – Multiple...

Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

– Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish maximum tolerated dose – – Multiple ascending dose (MAD) cohort to c...

Moleculin to Present at the H.C. Wainwright Global Investment Conference

HOUSTON, May 19, 2022 /PRNewswire/ --  Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin...

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

– Positive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies – – Multiple key clinical and regulatory milestones expected throughout 2022 –...

Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Ame...

– Dosing for first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers and establish maximum tolerated dose expected to commence imminently – HOUSTON , May 10...

Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Trea...

– Preliminary positive safety and efficacy data from second Phase 1 AML study validate advancement to Phase 1/2 of Annamycin in combination with Cytarabine – Preclinical animal research demonstrated a 6...

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Global leader with a distinguished 30-year career in oncology, hematology, and academia with significant contributions in clinical developments in ovarian cancer, lung cancer, and leukemias and lymphoma...

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

Investigational New Drug (IND) application clearance from FDA opens up potential for additional investigator funded and led clinical studies   HOUSTON , April 21, 2022 /PRNewswire/ -- Moleculin Biotech,...

Moleculin Announces Corporate Rebranding and Launch of New Website

Company reiterates commitment to solving some of the toughest challenges in highly resistant cancers and viruses and developing better treatments that can make a real impact in people's lives HOUSTON, A...

Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting

Annamycin exhibited robust antitumor activity in experimental colorectal cancer liver and lung metastasis models Results support advancement of preclinical development toward initiating clinical studies...

Moleculin Reports Full Year Financial Results and Provides Programs Update

– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine – – Preliminary interim data for Annamycin...

Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

HOUSTON , March 23, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target...

Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference

HOUSTON, March 11, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti...

Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

HOUSTON, March 1, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin...

Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal Study

Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, evaluating Annamycin for relapsed and refractory acute ...

Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development

HOUSTON, Feb. 14, 2022 /PRNewswire/ --  Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti...

WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech

VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that it has entered into an amended and r...

Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference

HOUSTON, Jan. 20, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myel...

HOUSTON, Jan. 18, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin...

Moleculin to Present at the H.C. Wainwright BioConnect Conference

HOUSTON, Jan. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment...

HOUSTON, Dec. 27, 2021 /PRNewswire/ --  Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti...

Read Why Is Roth Capital Bullish On This Cancer-Focused Stock

Roth Capital notes that the FDA cleared Moleculin Biotech Inc's (NASDAQ:MBRX) WP1122 to start a Phase 1 trial in glioblastoma multiforme, which will be in addition to the drug's impending parallel clini...